NBC Los Angeles5h
Jim Cramer explains how to find buying opportunities in this market
CNBC's Jim Cramer reviewed recent market action as earnings season stretches on, telling investors how to spot unwarranted ...
Belite Bio: The Picture Is Still Unclear
Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...
Why NIKE (NKE) Is a Top Luxury Clothing Stock to Buy
We recently published a list of the Top 12 Luxury Clothing Stocks to Buy According to Hedge Funds. In this article, we are ...
Why Nordstrom (JWN) Is a Top Luxury Clothing Stock to Buy
We recently published a list of the Top 12 Luxury Clothing Stocks to Buy According to Hedge Funds. In this article, we are ...
Why Lululemon Athletica (LULU) Is a Top Luxury Clothing Stock to Buy
We recently published a list of the Top 12 Luxury Clothing Stocks to Buy According to Hedge Funds. In this article, we are ...
Why Ralph Lauren (RL) Is a Top Luxury Clothing Stock to Buy
We recently published a list of the Top 12 Luxury Clothing Stocks to Buy According to Hedge Funds. In this article, we are ...
Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...
3 Magnificent Stocks to Buy and Hold Forever
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...
‘A bull with a lowercase b': Stock market experts say to prepare for continued growth, but more volatility, in 2025
The last two years have been just about as good as stock investors could have hoped for. Here’s what to expect going forward.
'Buy the dip and sell the rips' - stock traders are counting on the 'Trump put'
Accordingly, traders should adopt a strategy of "buy the dip and sell the rips." Lighten or short positions when the market ...
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...
5 most overvalued housing markets in 2025 — including one where mortgage costs exceed average income
In a survey of the country’s most overvalued housing markets, US News & World Report found a number of major cities where ...